Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsNCT Number: NCT03108573
This study evaluates different optimized MRI sequences for the detection of brain lesions in patients with multiple sclerosis in comparison with the recommended FLAIR sequence
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
MRI is a tool of choice for detecting demyelinating lesions in Multiple Sclerosis (MS) disease. On a consensual basis, the detection of those lesions in done on FLAIR (FLuid Attenuated Inversion Recovery) sequences, weighted T2 with cancelling of fluid signal, leading to a much better contrast between the lesion and the environment. The environment is displayed as a iso-signal for the surrounding healthy brain's white matter and as a hypo-signal for the fluids. Keys parameters indicative of the sequence's contrast are the echo time, the reversal time, and the repetition time, wich seems to be crucial to detect the lesions, according to relatively discordant results of publications using different technologies of FLAIR. Although 3D FLAIR sequences play an essential role for diagnosis and evaluation (evolution under treatment, prognosis) of demyelinating pathologies there is no consensus on parameters used on routine basis.
The aim of the trial is to discover the optimal combination of theses parameters so as to well detect the lesions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline
quantification of lesions on each sequence
Time frame: baseline
proportion of lesions localised in cerebellum or brainstem, on each sequence
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: FLAIR-SEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsNCT02511028
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bethesda, Maryland, United States
View Trial DetailsNCT07175792
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Diepenbeek, Belgium
View Trial DetailsNCT07726667
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Gaziantep, Gaz, Turkey (Türkiye)
View Trial Details